Filed by the Registrant ☒
|
Filed by a Party other than the Registrant ☐
|
☐ |
Preliminary Proxy Statement
|
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☐ |
Definitive Proxy Statement
|
☒ |
Definitive Additional Materials
|
☐ |
Soliciting Material under § 240.14a-12
|
☒ |
No fee required.
|
☐ |
Fee paid previously with preliminary materials.
|
☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
||
Equillium, Inc.
2223 Avenida de la Playa, Suite 105
La Jolla, California 92037
(858) 240-1200
Attn: Investor Relations
|
Metacrine, Inc.
4225 Executive Square, Suite 600
San Diego, CA 92037
(858) 369-7800
Attn: Investor Relations
|
All Transactions
|
Total
Transaction
Value1
|
1 Day
Prior
Implied
Premium
+
Fees
|
5 Day
Prior
Implied
Premium
+
Fees
|
10 Day
Prior
Implied Premium + Fees
|
15 Day
Prior
Implied
Premium
+
Fees
|
||||||||||||||
Minimum:
|
$0.5
|
1.67
|
%
|
-21.77
|
%
|
-31.17
|
%
|
-27.70
|
%
|
||||||||||
Lower (First) Quartile:
|
$2.7
|
11.99
|
%
|
6.09
|
%
|
2.29
|
%
|
3.57
|
%
|
||||||||||
Median:
|
$10.0
|
21.29
|
%
|
23.05
|
%
|
23.56
|
%
|
20.74
|
%
|
||||||||||
Average:
|
$17.8
|
26.22
|
%
|
22.08
|
%
|
22.74
|
%
|
19.91
|
%
|
||||||||||
Upper (Third) Quartile:
|
$25.0
|
35.16
|
%
|
36.38
|
%
|
38.78
|
%
|
32.95
|
%
|
||||||||||
Maximum:
|
$85.0
|
76.52
|
%
|
81.28
|
%
|
105.46
|
%
|
79.92
|
%
|
2022 Transactions
|
Total
Transaction
Value1
|
1 Day
Prior
Implied
Premium
+
Fees
|
5 Day
Prior
Implied
Premium
+
Fees
|
10 Day
Prior
Implied Premium + Fees
|
15 Day
Prior
Implied Premium + Fees
|
||||||||||||||
Minimum:
|
$3.5
|
8.07
|
%
|
-7.86
|
%
|
-13.36
|
%
|
4.12
|
%
|
||||||||||
Lower (First) Quartile:
|
$12.1
|
10.50
|
%
|
1.67
|
%
|
11.34
|
%
|
16.18
|
%
|
||||||||||
Median:
|
$15.4
|
15.58
|
%
|
24.37
|
%
|
43.10
|
%
|
49.09
|
%
|
||||||||||
Average:
|
$27.5
|
20.51
|
%
|
24.57
|
%
|
41.75
|
%
|
44.02
|
%
|
||||||||||
Upper (Third) Quartile:
|
$33.7
|
22.29
|
%
|
47.38
|
%
|
64.37
|
%
|
69.82
|
%
|
||||||||||
Maximum:
|
$85.0
|
50.52
|
%
|
57.37
|
%
|
105.46
|
%
|
79.92
|
%
|
2021 Transactions
|
Total
Transaction
Value
|
1 Day
Prior
Implied
Premium
+
Fees
|
5 Day
Prior
Implied
Premium
+
Fees
|
10 Day
Prior
Implied
Premium
+
Fees
|
15 Day
Prior
Implied Premium + Fees
|
||||||||||||||
Minimum:
|
$1.0
|
3.14
|
%
|
-21.77
|
%
|
-20.20
|
%
|
-27.70
|
%
|
||||||||||
Lower (First) Quartile:
|
$7.5
|
20.38
|
%
|
-6.16
|
%
|
-8.46
|
%
|
-14.98
|
%
|
||||||||||
Median:
|
$15.0
|
32.26
|
%
|
8.23
|
%
|
6.94
|
%
|
0.73
|
%
|
||||||||||
Average:
|
$19.9
|
35.43
|
%
|
18.77
|
%
|
13.22
|
%
|
9.20
|
%
|
||||||||||
Upper (Third) Quartile:
|
$25.1
|
57.00
|
%
|
43.48
|
%
|
26.38
|
%
|
27.98
|
%
|
||||||||||
Maximum:
|
$75.0
|
76.52
|
%
|
81.28
|
%
|
74.04
|
%
|
65.35
|
%
|
2021 Transactions
|
Total
Transaction
Value
|
1 Day
Prior
Implied
Premium
+
Fees
|
5 Day Prior Implied Premium +
Fees
|
10 Day
Prior
Implied Premium + Fees
|
15 Day Prior
Implied
Premium +
Fees
|
||||||||||||||
Minimum:
|
$1.0
|
3.14
|
%
|
-21.77
|
%
|
-20.20
|
%
|
-27.70
|
%
|
||||||||||
Lower (First) Quartile:
|
$7.5
|
16.12%
|
|
-11.24%
|
|
-9.37%
|
|
-13.27%
|
|
||||||||||
Median:
|
$14.5
|
32.26
|
%
|
4.69%
|
|
6.63%
|
|
0.73
|
%
|
||||||||||
Average:
|
$14.9
|
33.07%
|
|
13.33%
|
|
8.23%
|
|
6.02%
|
|
||||||||||
Upper (Third) Quartile:
|
$21.6
|
51.15%
|
|
42.85%
|
|
24.24%
|
|
22.93%
|
|
||||||||||
Maximum:
|
$34.6
|
70.23%
|
|
54.69%
|
|
52.00%
|
|
50.38%
|
|
($ in millions)
|
2022E
|
|
2023E
|
|
2024E
|
|
2025E
|
|
2026E
|
2027E
|
|
2028E
|
|
2029E
|
|
2030E
|
|
2031E
|
|
2032E
|
|
2033E
|
|
2034E
|
2035E
|
|
2036E
|
|
2037E
|
|
2038E
|
|
|||||||||||||||||||
EBIT
|
($56
|
)
|
($17
|
)
|
($39
|
)
|
($29
|
)
|
($75
|
)
|
($60
|
)
|
$9
|
$85
|
$134
|
$174
|
$177
|
$181
|
$190
|
$193
|
$194
|
$195
|
$203
|
||||||||||||||||||||||||||||
(-) Taxes
|
-
|
-
|
-
|
-
|
-
|
-
|
(0
|
)
|
(3
|
)
|
(5
|
)
|
(7
|
)
|
(14
|
)
|
(38
|
)
|
(39
|
)
|
(40
|
)
|
(40
|
)
|
(41
|
)
|
(42
|
)
|
|||||||||||||||||||||||
NOPAT
|
($56
|
)
|
($17
|
)
|
($39
|
)
|
($29
|
)
|
($75
|
)
|
($60
|
)
|
$9
|
$81
|
$129
|
$167
|
$163
|
$143
|
$150
|
$153
|
$154
|
$154
|
$161
|
||||||||||||||||||||||||||||
(-) Change in Net Working Capital
|
(2
|
)
|
(1
|
)
|
2
|
(1
|
)
|
2
|
(4
|
)
|
(5
|
)
|
(9
|
)
|
(6
|
)
|
(5
|
)
|
(1
|
)
|
(1
|
)
|
(1
|
)
|
(1
|
)
|
(0
|
)
|
(0
|
)
|
(1
|
)
|
|||||||||||||||||||
Free Cash Flow
|
($59
|
)
|
($18
|
)
|
($37
|
)
|
($31
|
)
|
($73
|
)
|
($63
|
)
|
$4
|
$72
|
$123
|
$162
|
$163
|
$143
|
$149
|
$152
|
$153
|
$154
|
$160
|
($ in millions)
|
2023E
|
|
2024E
|
|
2025E
|
2026E
|
|
2027E
|
|
2028E
|
|
2029E
|
|
2030E
|
|
2031E
|
|
2032E
|
|
2033E
|
|
2034E
|
|
2035E
|
|
2036E
|
|
2037E
|
|
2038E
|
|
|||||||||||||||||
EBIT
|
($8
|
)
|
($37
|
)
|
($24
|
)
|
($75
|
)
|
($58
|
)
|
$9
|
$85
|
$134
|
$174
|
$177
|
$181
|
$190
|
$193
|
$194
|
$195
|
$203
|
|||||||||||||||||||||||||||
(-) Taxes
|
-
|
-
|
-
|
-
|
-
|
(0
|
)
|
(3
|
)
|
(5
|
)
|
(7
|
)
|
(19
|
)
|
(38
|
)
|
(39
|
)
|
(40
|
)
|
(40
|
)
|
(41
|
)
|
(42
|
)
|
|||||||||||||||||||||
NOPAT
|
($8
|
)
|
($37
|
)
|
($24
|
)
|
($75
|
)
|
($58
|
)
|
$9
|
$81
|
$129
|
$167
|
$158
|
$143
|
$150
|
$153
|
$154
|
$154
|
$161
|
|||||||||||||||||||||||||||
(-) Change in Net Working Capital
|
(1
|
)
|
3
|
(2
|
)
|
2
|
(4
|
)
|
(5
|
)
|
(9
|
)
|
(6
|
)
|
(5
|
)
|
(1
|
)
|
(1
|
)
|
(1
|
)
|
(1
|
)
|
(0
|
)
|
(0
|
)
|
(1
|
)
|
||||||||||||||||||
Free Cash Flow
|
($9
|
)
|
($34
|
)
|
($26
|
)
|
($72
|
)
|
($62
|
)
|
$4
|
$72
|
$123
|
$162
|
$158
|
$143
|
$149
|
$152
|
$153
|
$154
|
$160
|
• |
KalVista Pharmaceuticals, Inc. ($247)
|
• |
MoonLake Immunotherapeutics ($216)
|
• |
Allakos Inc. ($87)
|
• |
VectivBio Holding AG ($59)
|
• |
Immunic Inc. ($48)
|
• |
Abivax Societe Anonyme ($122)
|
• |
Akari Therapeutics Plc ($61)
|
• |
X4 Pharmaceuticals, Inc. ($59)
|
• |
Applied Molecular Transport Inc. (– $41)
|
Publicly Traded Comparable Company
|
Equity
Value
($ millions)
|
||
VectivBio Holding AG
|
$105
|
||
Allakos Inc.
|
$135
|
($ in millions)
|
2022E
|
|
2023E
|
|
2024E
|
|
2025E
|
|
2026E
|
|
2027E
|
|
2028E
|
|
2029E
|
|
2030E
|
|
2031E
|
|
2032E
|
|
2033E
|
|
2034E
|
|
2035E
|
|
2036E
|
|
2037E
|
|
2038E
|
|
|||||||||||||||||
G&A Savings
|
$15
|
$12
|
$12
|
$6
|
$3
|
$3
|
$3
|
$3
|
$3
|
$3
|
$3
|
$3
|
$3
|
$3
|
$3
|
$3
|
$3
|
Varying Sensitivity Inputs
|
Metacrine
Liquidation Analysis
Per Share Value
|
Implied Pro Forma
Metacrine Per Share
Value Range
|
||||
Cumulative aGVHD POS (40% - 80%) and Combined Company WACC (13.5% - 17.5%)
|
||||||
High End of the Collar (0.151x Exchange Ratio)
|
$0.58
|
$0.52 - $0.89
|
||||
Implied 0.243x Exchange Ratio, (as of 09/01/2022)
|
$0.58
|
$0.76 - $1.30
|
||||
Low End of the Collar (0.251x Exchange Ratio)
|
$0.58
|
$0.78 - $1.33
|
($ in millions)
|
2022E
|
|
2023E
|
|
2024E
|
|
2025E
|
|
2026E
|
|
2027E
|
|
2028E
|
|
2029E
|
|
2030E
|
|
2031E
|
|
2032E
|
|
2033E
|
|
2034E
|
|
2035E
|
|
2036E
|
|
2037E
|
|
2038E
|
|
|||||||||||||||||
EBIT
|
($80
|
)
|
($54
|
)
|
($89
|
)
|
($107
|
)
|
($113
|
)
|
($63
|
)
|
$62
|
$167
|
$264
|
$319
|
$441
|
$322
|
$508
|
$235
|
$547
|
$543
|
$534
|
||||||||||||||||||||||||||||
(-) Taxes
|
-
|
-
|
-
|
-
|
-
|
-
|
(2
|
)
|
(7
|
)
|
(11
|
)
|
(13
|
)
|
(90
|
)
|
(67
|
)
|
(106
|
)
|
(49
|
)
|
(114
|
)
|
(113
|
)
|
(111
|
)
|
|||||||||||||||||||||||
NOPAT
|
($80
|
)
|
($54
|
)
|
($89
|
)
|
($107
|
)
|
($113
|
)
|
($63
|
)
|
$60
|
$161
|
$254
|
$306
|
$351
|
$255
|
$402
|
$186
|
$433
|
$430
|
$424
|
||||||||||||||||||||||||||||
(-) Change in Net Working Capital
|
-
|
-
|
-
|
(2
|
)
|
(1
|
)
|
(7
|
)
|
(11
|
)
|
(14
|
)
|
(14
|
)
|
(11
|
)
|
(6
|
)
|
(4
|
)
|
(5
|
)
|
(4
|
)
|
(2
|
)
|
0
|
1
|
||||||||||||||||||||||
Free Cash Flow
|
($80
|
)
|
($54
|
)
|
($89
|
)
|
($108
|
)
|
($114
|
)
|
($70
|
)
|
$49
|
$147
|
$239
|
$295
|
$345
|
$251
|
$397
|
$182
|
$431
|
$430
|
$424
|
• |
KalVista Pharmaceuticals, Inc. (– $30)
|
• |
MoonLake Immunotherapeutics ($222)
|
• |
VectivBio Holding AG ($159)
|
• |
Immunic Inc. ($232)
|
• |
Abivax Societe Anonyme ($155)
|
• |
Akari Therapeutics Plc ($58)
|
• |
X4 Pharmaceuticals, Inc. ($114)
|
• |
Applied Molecular Transport Inc. (– $44)
|
Publicly Traded Comparable Company
|
Equity
Value
($ millions)
|
|||
Akari Therapeutics Plc
|
|
$80
|
||
X4 Pharmaceuticals, Inc.
|
|
$130
|
Metric
|
Metric
Range
($ millions)
|
Implied
Equillium
Price Per
Share
|
||||||
Equity Value
|
|
$125 - $175
|
|
$3.70 - $5.05
|
Varying Sensitivity Inputs
|
Total Pro Forma
Metacrine Per Share
Value Range
(in millions)
|
Implied Pro Forma
Metacrine Per Share
Value Range
|
||||||
Cumulative aGVHD POS (40% - 80%) and Combined Company WACC (14.0% - 18.0%)
|
||||||||
Low End of the Collar (0.282x Exchange Ratio)
|
$300-$615
|
|
$6.30 - $12.70
|
IX]5QWK13-$SN4N5QUJ43KZUQB:O_ +56(]6R
M>M:QK(=SKA*I[T[>*YV'4-W>KT5UN[UK[9!P,TY+Y1WJC/J*X/-8%SJ
M)!^]65/J39ZUQ5:YG*1L7M[NS@UB33L2>:A^U&3O2$YK@G5,&QC2MZTSS&SU
MIQ%-Q7/*H3>Q(#Q4;=:<.E(14N8KBK3^*BSBGJU/=#'4A-!/%,YII#2#/-2
MC%1[32X:J4#2PXF@)FFA&)Z5=MX2>U:1@58@%N33ULV/:MB"TSVK1AT\'M6\
M8$VU.;6P;TJQ'8-GI74IIHQTJ==. [5M&E :@>W![5
M:J$RHG&W5AG/%8MSIQSTKT*6R![50GTT$'BMHU3GJ4[(X$VNSJ*HW0*]*ZV_
ML]F<"N=NH#SQ71%W1QR5C+@E97ZUT.FWI##)KGWC*'I4MM.4?K3>PX.QZ?I]
M\"@&:VH9@PKSS3K\_*,UUUA=!E'-<U1M9JW:KM%'*@,QM/3TJ&33UQ
MTK8-1NN:RE%"L<_-9 =JS;B J#@5U,D.>U4YK+<#Q6?(%CB+EI4;C--BEE]Z
MZ:?2=QZ5&ND8_AIN+2*,^VFDXS6K!<'N:A:R\OM4+,8Z2#H;L-T.,FKT=TF.
MM<@;TIWI4U4YQFK3)1V@G4]Z>) :Y>#4"V.:U;>YW#K5J11J@TM0QOFIJH04
M444 +12455P%HI*6BX!1113 **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BDHJ;@%)FD)J-Y0!UK*4K -DFV
MUGW%Z #S4=[<@9P:YZ\O3SS7)4K6T(DRU>WV0>:YV[N"Q/-,GO"Q/-4BY=J\
M^I4N9$,FYGJ2,>M3"/(S2%=IKEE(0]:4TQ33LUS-W8FQ"*;BGTAIJG
M,=B:X:E4ALA89-.5
M* .:F&,5S.=Q7 <"H7-2L:@:HKYJ$J:M,-^GK5*+,G4-'=1NK-^W)ZT?;T]:?(R%6-0-3@:S!?
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MJD#[UE
M7H[1<=*NI;@=JG6+%8RJG3&B4?LBXZ5$]H/2M;RZC:+-2J@Y43#DLQZ5EW=C
MG.!76-!GM5>2S#=JU58YY8>YPDVGG)XJA/8$#I7?2Z2LR[T\ 'BMHU;G-.
MERG 2VY0]*C20HXYKH+ZSVYXKGKA"DG2JO2EIC1;+N<5'*-TIJ]8Q9<5U-Z&$7